Neurosterix completes Phase 1 for NTX-253 in schizophrenia
Addex Therapeutics said its 20%-owned spin-out Neurosterix completed Phase 1 studies of NTX-253 and plans to advance it into Phase 2 for schizophrenia.
Addex Therapeutics said its 20%-owned spin-out Neurosterix completed Phase 1 studies of NTX-253 and plans to advance it into Phase 2 for schizophrenia.